VOR

SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

3 - Vor Biopharma Inc. (0001817229) (Issuer)

SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

4 - Vor Biopharma Inc. (0001817229) (Issuer)

3 - Vor Biopharma Inc. (0001817229) (Issuer)

SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 42,650 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 9,050 shares of Vor Bio's common stock to 9 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Induc

Jefferies initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $50.00

S-8 - Vor Biopharma Inc. (0001817229) (Filer)

10-K - Vor Biopharma Inc. (0001817229) (Filer)

First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease $75 million private placement strengthens balance sheet and supports telitacicept global clinical development Pro-forma cash and investment balance of $530.2 million as of December 31, 2025 expected to provide runway into early 2029 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update. "Over the past six months, Vor Bio repositioned the compa

BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first patient in UPSTREAM SjD, a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating telitacicept in adult patients with active primary Sjögren's disease (SjD), formerly known as Sjögren's syndrome. "Dosing the first patient in the global Phase 3 UPSTREAM SjD trial represents a significant milestone for telitacicept and for patients living with Sjögren's disease. As the only BAFF/APRIL inhibitor currently in Phase 3 development for this condition, we believe telitacicept has th

8-K - Vor Biopharma Inc. (0001817229) (Filer)

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $75 million, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions. The fin

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 215,700 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 46,235 shares of Vor Bio's common stock to 8 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor B

Wells Fargo initiated coverage of Vor Biopharma with a rating of Overweight and set a new price target of $30.00

SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA. Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ETLocation: Regis A live webcast and archived replay of the presentation will be remain available for a period of 90 days on the Company's website at: https://ir.vorbio.com/events-presentations/ About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidl

SCHEDULE 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

SCHEDULE 13G/A - Vor Biopharma Inc. (0001817229) (Subject)